January 2023 sees the launch of TVM‘s DogStem, a ready to use stem cell treatment for canine osteoarthritis of the hip and elbow, proven to reduce pain and lameness and improve mobility and quality of life.
DogStem is the first licensed stem cell treatment for dogs with mild to severe osteoarthritis.
It has long-term efficacy (from 3 to more than 12 months) following a single injection (DogStem suspension for injection for dogs SPC).
As a ready to use product that can be ordered from your wholesaler or direct from the DogStem website, the procedure and process of using stem cell therapy in practice is simplified.
Current stem cell treatments require a surgical harvesting procedure carried out under general anaesthetic, which incurs additional cost, is less convenient and can result in in scarring or other complications.
Until now, there have been no licensed stem cell treatments available, and the complexities associated with current options have limited their use in veterinary practice.
In a prospective randomised double-blinded and placebo-controlled trial of DogStem, results showed that:
- 63 percent of dogs showed a clinically relevant improvement in force-plate gait analysis eight weeks after treatment
- 77 percent had an improved orthopaedic examination by week eight
- 60 percent of owners reported improvement in walking, 27 percent in playing with other dogs and 42 percent reported reduced stiffness after sleeping 12 to18 months after administration
- 65 percent of owners considered the treatment improved their pet’s quality of life eight weeks after treatment
- 59 percent reported the treatment’s effects lasted longer than six months
Helen Harrison, DogStem technical vet and product manager said: “Osteoarthritis is one of the most common diseases seen in veterinary practices and is challenging to manage.
“Conventional medical treatments typically address the symptoms rather than the underlying pathological processes.
“At the same time, local treatment options that slow progression of osteoarthritis have been limited and surgical interventions aren’t always possible or may be unrewarding.
“We’re delighted to be able to offer vets DogStem, a stem cell product with a strong evidence base across numerous mobility and quality of life parameters.’
For more information visit the website or contact your local Territory Manager.
